RG
NRIX icon

Redmile Group’s Nurix Therapeutics NRIX Stock Holding History

Redmile Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.8M Sell
4,073,787
-3,659,021
-47% -$62.3M 6.64% 5
2026
Q1 		$120M Sell
7,732,808
-361,100
-4% -$5.99M 7.94% 5
2025
Q4 		$154M Buy
8,093,908
+4,415,514
+120% +$63.4M 11.31% 3
2025
Q3 		$34M Sell
3,678,394
-54,494
-1% -$566K 3.31% 10
2025
Q2 		$42.5M Sell
3,732,888
-319,039
-8% -$3.45M 4.53% 7
2025
Q1 		$48.1M Sell
4,051,927
-140,700
-3% -$2.35M 4.55% 5
2024
Q4 		$79M Sell
4,192,627
-88,354
-2% -$2.03M 5.51% 3
2024
Q3 		$96.2M Sell
4,280,981
-142,635
-3% -$3.23M 5.67% 2
2024
Q2 		$92.3M Sell
4,423,616
-59,400
-1% -$925K 5.58% 3
2024
Q1 		$65.9M Buy
4,483,016
+1,226,497
+38% +$13.2M 2.42% 12
2023
Q4 		$33.6M Buy
3,256,519
+407,692
+14% +$2.79M 1.2% 25
2023
Q3 		$22.4M Sell
2,848,827
-8,482
-0.3% -$77.4K 1.07% 30
2023
Q2 		$28.5M Buy
2,857,309
+107,925
+4% +$1.1M 1.1% 28
2023
Q1 		$24.4M Sell
2,749,384
-251,400
-8% -$2.62M 1.06% 38
2022
Q4 		$32.9M Sell
3,000,784
-5,900
-0.2% -$71.2K 1.35% 24
2022
Q3 		$39.2M Hold
3,006,684
– – 1.52% 21
2022
Q2 		$38.1M Sell
3,006,684
-12,100
-0.4% -$137K 1.45% 23
2022
Q1 		$42.3M Buy
3,018,784
+60,500
+2% +$1.07M 1.32% 21
2021
Q4 		$85.6M Sell
2,958,284
-134,793
-4% -$4.09M 1.95% 14
2021
Q3 		$92.7M Sell
3,093,077
-97,000
-3% -$2.99M 1.62% 22
2021
Q2 		$84.6M Sell
3,190,077
-124,040
-4% -$3.64M 1.25% 26
2021
Q1 		$103M Buy
3,314,117
+467,992
+16% +$17.7M 1.45% 20
2020
Q4 		$93.6M Buy
2,846,125
+252,555
+10% +$8.37M 1.13% 27
2020
Q3 		$90.5M Buy
+2,593,570
New +$65.4M 1.66% 15

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Redmile Group's NRIX Position: Q2 2026 in Review

Redmile Group reduced its Nurix Therapeutics (NRIX) stake by 47% in Q2 2026, selling an estimated $62.3M and leaving 4,073,787 shares worth $98.8M. The position accounts for 6.64% of the portfolio, ranked #5.

Redmile Group first reported a position in NRIX in Q3 2020 and has held it in 24 quarters since. The position peaked at $154M in Q4 2025. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Redmile Group held 4,073,787 shares of Nurix Therapeutics worth $98.8M as of Q2 2026.
  • Redmile Group sold 3,659,021 Nurix Therapeutics shares in Q2 2026, an estimated $62.3M.
  • Nurix Therapeutics made up 6.64% of Redmile Group's portfolio in Q2 2026, its #5 holding.
  • Redmile Group first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Redmile Group's Nurix Therapeutics position peaked at $154M in Q4 2025.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Redmile Group's 13F filing for Q2 2026, filed 14 Aug 2026.